Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.

Journal of cutaneous pathology - 1 Dec 2017

Dai Julia, Kunder Christian A, Chu Emily Y, Chan Edward F, Egan Christine L, Novoa Roberto A

Abstract excerpt

Treatment with BRAF inhibitors may lead to paradoxical mitogen-activated protein kinase (MAPK) pathway activation and accelerated tumorigenesis in cells with preexisting oncogenic hits. This phenomenon manifests clinically in the development of squamous cell carcinomas (SCCs) and keratoacanthomas (KAs) in patients treated with BRAF inhibitors. Cases of extracutaneous malignancies associated with BRAF inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Awareness
Share to Hemangiosarcoma
Share to Mitogen-Activated Protein Kinase 1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Physicians

Share to Positron Emission Tomography Computed Tomography

Share to Proto-Oncogene Proteins c-ret

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 28796396
DOI: 10.1111/cup.13024

Genes

BRAF
RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.PMID 28796396Read ↗

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.Semantic proximity Read ↗

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.Semantic proximity Read ↗

Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.Semantic proximity Read ↗

Vemurafenib-associated keratoses with genetic heterogeneity of RAS.Semantic proximity Read ↗

Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy.Semantic proximity Read ↗

Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen-activated protein kinase pathway.Semantic proximity Read ↗

Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.Semantic proximity Read ↗

High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.Semantic proximity Read ↗

Cutaneous angiosarcoma: a current update.Semantic proximity Read ↗

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.Semantic proximity Read ↗

Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.Semantic proximity Read ↗

Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.